Search CTL/CD8+ T-Cell Epitope Database

Found 8 matching records:

Displaying record number 61316

HXB2 Location	Pol(131-140) Protease(75-84) DNA(2475..2504)	Pol Epitope Map
Author Location
Epitope	`VLVGPTPVNI`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	humanized mouse(A*0201)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, HLA binding, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	A clade, B clade, other, C clade

Notes

Strain HHD transgenic mice expressing a chimeric mouse-human HLA A*0201 were used to test whether breadth and depth of CTL response was greater to tHIVconsv vaccine (HIV vaccine with A, B, C, D clade alternating consensus sequences from 14 HIV proteins and with a tissue plasmingoen activator leader sequence) combined with an HIVconsv-complementing multivalent mosaic immunogen tHIVcmo or to trivalent conserved mosaic immunogen vaccines. A hierarchy of tHIVconsv < tHIVconsv + tHIVcmo < tCmo1+tCmo2+tCmo3 was seen.
Immunodominant epitope VLVGPTPVNI was included in tHIVconsv and tCmo3 vaccine immunogens and elicited response with vaccine regimens of tHIVconsv+tHIVcmo, and tCmo1+tCmo2+tCmo3.

References

Abdul-Jawad2016 Sultan Abdul-Jawad, Beatrice Ondondo, Andy van Hateren, Andrew Gardner, Tim Elliott, Bette Korber, and Tomáš Hanke. Increased Valency of Conserved-Mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. Mol. Ther., 24(2):375-384, Feb 2016. PubMed ID: 26581160. Show all entries for this paper.

Displaying record number 61318

HXB2 Location	Pol(132-140) Protease(76-84) DNA(2478..2504)	Pol Epitope Map
Author Location
Epitope	`LVGPTPVNI`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	humanized mouse(A*0201)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, HLA binding, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	A clade, B clade, other, C clade

Notes

Strain HHD transgenic mice expressing a chimeric mouse-human HLA A*0201 were used to test whether breadth and depth of CTL response was greater to tHIVconsv vaccine (HIV vaccine with A, B, C, D clade alternating consensus sequences from 14 HIV proteins and with a tissue plasmingoen activator leader sequence) combined with an HIVconsv-complementing multivalent mosaic immunogen tHIVcmo or to trivalent conserved mosaic immunogen vaccines. A hierarchy of tHIVconsv < tHIVconsv + tHIVcmo < tCmo1+tCmo2+tCmo3 was seen.
Immunodominant epitope LVGPTPVNI was included in vaccine immunogens tHIVconsv and tCmo3 and elicited robust responses with vaccine regimens of tHIVconsv+tHIVcmo and particularly with tCmo1+tCmo2+tCmo3.

References

Displaying record number 61315

HXB2 Location	Pol(335-344) RT(180-189) DNA(3087..3116)	Pol Epitope Map
Author Location
Epitope	`IYQYMDDLYV`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	humanized mouse(A*0201)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, HLA binding, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	A clade, B clade, other, C clade

Notes

Strain HHD transgenic mice expressing a chimeric mouse-human HLA A*0201 were used to test whether breadth and depth of CTL response was greater to tHIVconsv vaccine (HIV vaccine with A, B, C, D clade alternating consensus sequences from 14 HIV proteins and with a tissue plasmingoen activator leader sequence) combined with an HIVconsv-complementing multivalent mosaic immunogen tHIVcmo or to trivalent conserved mosaic immunogen vaccines. A hierarchy of tHIVconsv < tHIVconsv + tHIVcmo < tCmo1+tCmo2+tCmo3 was seen.
Immunodominant epitope IYQYMDDLYV was included in tHIVconsv, tHIVcmo and tCmo3 vaccine immunogens and elicited response with vaccine regimens of tHIVconsv, tHIVconsv+tHIVcmo, and very robustly with tCmo1+tCmo2+tCmo3.

References

Displaying record number 61314

HXB2 Location	Pol(336-344) RT(181-189) DNA(3090..3116)	Pol Epitope Map
Author Location
Epitope	`YQYMDDLYV`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	humanized mouse(A*0201)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, HLA binding, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	A clade, B clade, other, C clade

Notes

Strain HHD transgenic mice expressing a chimeric mouse-human HLA A*0201 were used to test whether breadth and depth of CTL response was greater to tHIVconsv vaccine (HIV vaccine with A, B, C, D clade alternating consensus sequences from 14 HIV proteins and with a tissue plasmingoen activator leader sequence) combined with an HIVconsv-complementing multivalent mosaic immunogen tHIVcmo or to trivalent conserved mosaic immunogen vaccines. A hierarchy of tHIVconsv < tHIVconsv + tHIVcmo < tCmo1+tCmo2+tCmo3 was seen.
Immunodominant epitope YQYMDDLYV had the highest HLA-binding affinity as well. It was included in tHIVconsv, tHIVcmo and tCmo3 vaccine immunogens and elicited response with vaccine regimens of tHIVconsv, tHIVconsv+tHIVcmo, and very robustly with tCmo1+tCmo2+tCmo3.

References

Displaying record number 61321

HXB2 Location	Pol(463-472) RT(308-317) DNA(3471..3500)	Pol Epitope Map
Author Location
Epitope	`EILKEPVHGV`	Epitope Alignment
Subtype	A, B, C, D
Species (MHC/HLA)	humanized mouse(A*0201)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, HLA binding, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	A clade, B clade, other, C clade

Notes

Strain HHD transgenic mice expressing a chimeric mouse-human HLA A*0201 were used to test whether breadth and depth of CTL response was greater to tHIVconsv vaccine (HIV vaccine with A, B, C, D clade alternating consensus sequences from 14 HIV proteins and with a tissue plasmingoen activator leader sequence) combined with an HIVconsv-complementing multivalent mosaic immunogen tHIVcmo or to trivalent conserved mosaic immunogen vaccines. A hierarchy of tHIVconsv < tHIVconsv + tHIVcmo < tCmo1+tCmo2+tCmo3 was seen.
Epitope EILKEPVHGV was not included in vaccine immunogens but elicited robust responses with vaccine regimens of tHIVcmo and tHIVconsv+tHIVcmo.

References

Displaying record number 61320

HXB2 Location	Pol(464-472) RT(309-317) DNA(3474..3500)	Pol Epitope Map
Author Location
Epitope	`ILKDPVHGV`	Epitope Alignment
Subtype	A, B, C, D
Species (MHC/HLA)	humanized mouse(A*0201)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, HLA binding, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	A clade, B clade, other, C clade

Notes

Strain HHD transgenic mice expressing a chimeric mouse-human HLA A*0201 were used to test whether breadth and depth of CTL response was greater to tHIVconsv vaccine (HIV vaccine with A, B, C, D clade alternating consensus sequences from 14 HIV proteins and with a tissue plasmingoen activator leader sequence) combined with an HIVconsv-complementing multivalent mosaic immunogen tHIVcmo or to trivalent conserved mosaic immunogen vaccines. A hierarchy of tHIVconsv < tHIVconsv + tHIVcmo < tCmo1+tCmo2+tCmo3 was seen.
Epitope ILKDPVHGV was included in vaccine immunogen tHIVconsv and elicited responses with vaccine regimens of tHIVconsv and tHIVconsv+tHIVcmo.

References

Displaying record number 61319

HXB2 Location	Vif(23-31) DNA(5107..5133)	Vif Epitope Map
Author Location
Epitope	`SLVKHHLTE`	Epitope Alignment
Subtype	A, B, C, D
Species (MHC/HLA)	humanized mouse(A*0201)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, HLA binding, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	A clade, B clade, other, C clade

Notes

Strain HHD transgenic mice expressing a chimeric mouse-human HLA A*0201 were used to test whether breadth and depth of CTL response was greater to tHIVconsv vaccine (HIV vaccine with A, B, C, D clade alternating consensus sequences from 14 HIV proteins and with a tissue plasmingoen activator leader sequence) combined with an HIVconsv-complementing multivalent mosaic immunogen tHIVcmo or to trivalent conserved mosaic immunogen vaccines. A hierarchy of tHIVconsv < tHIVconsv + tHIVcmo < tCmo1+tCmo2+tCmo3 was seen.
Epitope SLVKHHLTE was included in vaccine immunogens tHIVconsv, tCmo1 and tCmo3 and elicited responses with vaccine regimen of tHIVconsv.

References

Displaying record number 61317

HXB2 Location	gp160(103-111) gp120(103-111) DNA(6531..6557)	gp160 Epitope Map
Author Location
Epitope	`QMHEDIISL`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	humanized mouse(A*0201)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, HLA binding, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	A clade, B clade, other, C clade

Notes

Strain HHD transgenic mice expressing a chimeric mouse-human HLA A*0201 were used to test whether breadth and depth of CTL response was greater to tHIVconsv vaccine (HIV vaccine with A, B, C, D clade alternating consensus sequences from 14 HIV proteins and with a tissue plasmingoen activator leader sequence) combined with an HIVconsv-complementing multivalent mosaic immunogen tHIVcmo or to trivalent conserved mosaic immunogen vaccines. A hierarchy of tHIVconsv < tHIVconsv + tHIVcmo < tCmo1+tCmo2+tCmo3 was seen.
Immunodominant epitope QMHEDIISL was included in tHIVconsv, tHIVcmo, tCmo1 and tCmo3 vaccine immunogens and elicited response with vaccine regimens of tHIVconsv, particularly with tHIVconsv+tHIVcmo, and with tCmo1+tCmo2+tCmo3.